DICE Therapeutics, Inc.(DICE) Stock Research - Grey Stern Research

DICE Therapeutics, Inc. (DICE) Stock Analysis

$47.55 (0.06%)

DICE Financial Performance


Use the table below to view DICE Therapeutics, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2023

Metric Value Ranking among Peers
Price $47.55 -
52 Week Low $15.08 -
52 Week High $47.90 -
Market Cap $2.3 Billion 12/19
Gross Margin 0% 8/19
Profit Margin 0% 3/19
EBITDA margin -100% 3/19
Q2 - 2023 Revenue $0 8/19
Q2 - 2023 Earnings -$34.8 Million 7/19
Q2 - 2023 Free Cash Flow -$30.4 Million 9/19
Trailing 4 Quarters Revenue $0 13/19
Trailing 4 Quarters Earnings -$97.7 Million 6/19
Quarterly Earnings Growth -62% 15/19
Annual Earnings Growth -26% 9/19
Quarterly Revenue Growth 0% 6/19
Annual Revenue Growth 0% 7/19
Cash On Hand $73.5 Million 15/19
Short Term Debt $1.5 Million 10/19
Long Term Debt $11.0 Million 13/19

DICE Therapeutics, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare DICE Therapeutics, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 1/19
PS -1.00 13/19
PB 4.37 8/19
PC 30.91 4/19
Liabilities to Equity 0.06 12/19
ROA -0.18 5/19
ROE -0.19 7/19
Current Ratio 17.42 6/19
Quick Ratio 16.71 5/19
Long Term Debt to Equity 0.02 10/19
Debt to Equity 0.02 10/19
Burn Rate 2.06 11/19
Cash to Cap 0.03 15/19
CCR 0.87 6/19
EV to EBITDA -1.00 2/19
EV to Revenue -1.00 13/19

Company Details

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

CEO:

Website: https://www.dicemolecules.com

Address: 279 E. Grand Avenue South San Francisco, CA

Exchange: NASDAQ Global Market

Industry: Biotechnology

DICE Therapeutics, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to DICE Therapeutics, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Dyne Therapeutics, Inc. DYN $2.9 Billion
Cytokinetics, Incorporated CYTK $6.1 Billion
Ascendis Pharma A/S ASND $7.8 Billion
Crinetics Pharmaceuticals, Inc. CRNX $5.2 Billion
Karuna Therapeutics, Inc. KRTX $12.6 Billion
Pliant Therapeutics, Inc. PLRX $890.3 Million
Vaxcyte, Inc. PCVX $11.3 Billion
Chinook Therapeutics, Inc. KDNY $2.7 Billion
Edgewise Therapeutics, Inc. EWTX $3.0 Billion
Viridian Therapeutics, Inc. VRDN $1.6 Billion
Terns Pharmaceuticals, Inc. TERN $540.2 Million
Nuvalent, Inc. NUVL $6.7 Billion
Day One Biopharmaceuticals, Inc. DAWN $1.4 Billion
Immunocore Holdings plc IMCR $1.6 Billion
Acumen Pharmaceuticals, Inc. ABOS $137.0 Million
Arcellx, Inc. ACLX $4.8 Billion
Ventyx Biosciences, Inc. VTYX $173.2 Million
MoonLake Immunotherapeutics MLTX $3.2 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement

Latest News

DICE Income Statements
Quarter Year Revenue Earnings
Q2 2023 $ 0 -$34.8 Million
Q1 2023 $ 0 -$19.7 Million
Q4 2022 $ 0 -$22.6 Million
Q3 2022 $ 0 -$20.6 Million
Q2 2022 $ 0 -$21.5 Million
Q1 2022 $ 0 -$18.6 Million
Q4 2021 $ 0 -$25.6 Million
Q3 2021 $ 0 -$17.3 Million

View All

DICE Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2023 $73.5 Million $550.7 Million $12.6 Million $519.1 Million
Q1 2023 $101.6 Million $575.6 Million $12.9 Million -$213.2 Million
Q4 2022 $461.4 Million $594.0 Million $13.3 Million -$187.6 Million
Q3 2022 $48.3 Million $285.0 Million $13.6 Million $261.1 Million
Q2 2022 $16.8 Million $302.6 Million $13.9 Million $277.9 Million
Q1 2022 $53.7 Million $324.6 Million $14.1 Million $295.2 Million
Q4 2021 $115.8 Million $325.8 Million $0 $312.9 Million
Q3 2021 $311.6 Million $342.4 Million $2.4 Million $327.5 Million

View All

DICE Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2023 -$30.4 Million -$1.8 Million -$28.1 Million
Q1 2023 -$22.6 Million -$202,000 -$359.8 Million
Q4 2022 -$18.3 Million -$437,000 $413.1 Million
Q3 2022 -$30.4 Million -$909,000 $31.5 Million
Q2 2022 -$17.8 Million -$891,000 -$37.1 Million
Q1 2022 -$14.5 Million -$385,000 -$62.2 Million
Q4 2021 -$25.9 Million -$597,000 -$195.8 Million
Q3 2021 -$9.0 Million -$121,000 $296.1 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions